Amicus Therapeutics Inc [FOLD] stock prices are up 5.51% to $6.32 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The FOLD shares have gain 4.29% over the last week, with a monthly amount glided 6.22%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Amicus Therapeutics Inc [NASDAQ: FOLD] stock has seen the most recent analyst activity on July 17, 2025, when Morgan Stanley upgraded its rating to a Overweight but kept the price target unchanged to $108 for it. Previously, Morgan Stanley downgraded its rating to Equal-Weight on December 13, 2024, and dropped its price target to $12. On September 06, 2024, Jefferies initiated with a Buy rating and assigned a price target of $18 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $18 on May 30, 2024. Guggenheim upgraded its rating to a Buy but $13 remained the price target by the analyst firm on May 14, 2024. Morgan Stanley upgraded its rating to Overweight for this stock on December 19, 2023, and upped its price target to $20. In a note dated September 09, 2022, Morgan Stanley initiated an Equal-Weight rating and provided a target price of $14 on this stock.
The stock price of Amicus Therapeutics Inc [FOLD] has been fluctuating between $5.51 and $12.65 over the past year. Currently, Wall Street analysts expect the stock to reach $15.25 within the next 12 months. Amicus Therapeutics Inc [NASDAQ: FOLD] shares were valued at $6.32 at the most recent close of the market. An investor can expect a potential return of 141.3% based on the average FOLD price forecast.
Analyzing the FOLD fundamentals
The Amicus Therapeutics Inc [NASDAQ:FOLD] reported sales of 571.16M for trailing twelve months, representing a surge of 22.12%. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at 0.02%, Pretax Profit Margin comes in at -0.04%, and Net Profit Margin reading is -0.07%. To continue investigating profitability, this company’s Return on Assets is posted at -0.05, Equity is -0.2 and Total Capital is 0.02. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 2.17.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.05 points at the first support level, and at 5.77 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.47, and for the 2nd resistance point, it is at 6.62.
Ratios To Look Out For
It’s worth pointing out that Amicus Therapeutics Inc [NASDAQ:FOLD]’s Current Ratio is 3.21. In addition, the Quick Ratio stands at 2.29 and the Cash Ratio stands at 0.95. Considering the valuation of this stock, the price to sales ratio is 3.41, the price to book ratio is 9.53.
Transactions by insiders
Recent insider trading involved Campbell Bradley L, President and CEO, that happened on Feb 19 ’25 when 400.0 shares were sold. Director, BRADLEY CAMPBELL completed a deal on Feb 19 ’25 to buy 400.0 shares. Meanwhile, President and CEO Campbell Bradley L sold 7500.0 shares on Dec 02 ’24.
